Delivery Order SPE2DB22D3501-SPE2DB25FTL93

Award Date 11/13/24
Potential Completion Date 12/5/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm-fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $18,722.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The contract provides for the delivery of 4567313172 - REVLIMID 25 MG CAPSULE 21S, a pharmaceutical product, to...
This federal contract award, valued at $24,963.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award, valued at $52,896.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is a firm fixed price delivery order for the supply of REVLIMID 25 MG CAPSULE 100S, a pharmaceutical product. The award does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm fixed-price delivery order contract is for the supply of REVLIMID 15 MG CAPSULE 100S, a prescription medication. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor for this award, which is associated with a larger...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $178,310.12 firm fixed-price delivery order is for the supply of REVLIMID 10 MG CAPSULE 100S, a prescription medication. The contract has an ultimate completion date of December 24, 2024 and was awarded on December 3, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of April 11, 2025 and was awarded on March 21, 2025. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The $41,659.75 firm fixed price delivery order is for the supply of REVLIMID 10 MG CAPSULE 28S, a branded pharmaceutical product. The award has an ultimate completion date of May 3, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $37,445.14, is a delivery order for the supply of REVLIMID 20 MG CAPSULE 21S. It is a Firm Fixed Price contract with an ultimate completion date of April 2, 2025. The contract is not associated with a set-aside program. Amerisourcebergen Drug Corp is the prime contractor, and there is no mention of...
This federal contract award, valued at $89,155.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and an ultimate completion date of March 24, 2025. The contract is for the supply of REVLIMID 15 MG CAPSULE 100S, a pharmaceutical product. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FTL93
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the supply of REVLIMID 25 MG CAPSULE 21S, a specialty pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.

Generated 2/12/25, 9:12 AM